CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

CVM 2.19 -0.01 (-0.45%)
price chart
CEL-SCI Announces Robert Watson Joins Its Board of Directors
“I am excited to join CEL-SCI's board at this time, as the Company approaches evaluating the endpoint of its Phase 3 results, which may lead to a new and much needed immunotherapy to treat head and neck cancer.
CEL-SCI Corporation Releases Letter to Shareholders
Our Phase 3 study in advanced primary (untreated) head and neck cancer patients with the investigational drug Multikine* (Leukocyte Interleukin Inj.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Corporation (CVM) recently sold by insider Talor Eyal
CEL-SCI Corporation (NYSE:CVM) marched up 50.68% compared to a 52-week low price of $1.46. The shares were last seen trading 12.24% higher, taking the closing price at $2.2 on 01/22/2018.
CEL-SCI (NYSEAMERICAN:CVM)'s CSO Eyal Talor Unloaded 8192 Shares; Varian ...  Teletechwire (press release)
Active Stocks on Watch: Om Asset Management Ltd (OMAM) and Cel-Sci Corp (CVM)  Concord Register
CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate ...
CEL-SCI's LEAPS vaccine for the treatment of rheumatoid arthritis received a $1.5 million grant from the U.S. National Institutes of Health (NIH).
$0.52 EPS Expected for BofI Holding, Inc. (BOFI); Cel Sci (NYSEAMERICAN:CVM ...  Wolcott Daily
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
CEL-SCI Announces Adjustment to Warrant Exercise Price
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 ...
Cel Sci Corporation (NYSEAMERICAN:CVM)'s Stock Is Buy After Less Market ...  Frisco Fastball
Moody Stock Sees Increased Volatility Levels in Session: CEL-SCI Corporation ...
Taking a closer look into the volatility on shares of CEL-SCI Corporation (:CVM), we notice that the stock is 15.82% off of the 20-Day Simple Moving Average.
CEL-SCI Announces Update on Arbitration against Former Clinical Research ...
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...